DexCom Inc. (NASDAQ:DXCM) was upgraded by equities research analysts at Desjardins from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday.

Several other research firms also recently commented on DXCM. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of DexCom in a research report on Monday, June 20th. Jefferies Group reaffirmed a “positive” rating and issued a $98.00 target price on shares of DexCom in a research report on Friday, July 22nd. Canaccord Genuity reaffirmed a “buy” rating and issued a $95.00 target price on shares of DexCom in a research report on Wednesday, July 13th. Leerink Swann reaffirmed an “outperform” rating and issued a $90.00 target price on shares of DexCom in a research report on Wednesday, July 20th. Finally, Deutsche Bank AG upped their target price on DexCom from $90.00 to $98.00 and gave the company a “buy” rating in a research report on Friday, July 15th. Four research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $94.96.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

DexCom (NASDAQ:DXCM) opened at 93.06 on Friday. DexCom has a 12 month low of $47.92 and a 12 month high of $100.72. The firm has a 50-day moving average price of $91.81 and a 200 day moving average price of $75.54. The company’s market cap is $7.81 billion.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Tuesday, August 2nd. The medical device company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.12. The business had revenue of $137.30 million for the quarter, compared to analyst estimates of $132.48 million. DexCom had a negative return on equity of 19.68% and a negative net margin of 16.42%. DexCom’s quarterly revenue was up 47.3% compared to the same quarter last year. During the same period last year, the firm earned ($0.05) EPS. On average, equities analysts expect that DexCom will post ($0.57) earnings per share for the current year.

In related news, SVP Jeffrey Moy sold 4,557 shares of the stock in a transaction on Wednesday, June 29th. The stock was sold at an average price of $80.00, for a total value of $364,560.00. Following the completion of the sale, the senior vice president now directly owns 76,333 shares in the company, valued at $6,106,640. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Terrance H. Gregg sold 40,000 shares of the stock in a transaction on Friday, August 19th. The shares were sold at an average price of $90.70, for a total value of $3,628,000.00. Following the completion of the sale, the insider now owns 451,486 shares of the company’s stock, valued at $40,949,780.20. The disclosure for this sale can be found here. 2.80% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the stock. BlackRock Fund Advisors increased its stake in DexCom by 0.6% in the first quarter. BlackRock Fund Advisors now owns 929,897 shares of the medical device company’s stock worth $63,149,000 after buying an additional 5,443 shares during the last quarter. BlackRock Group LTD increased its stake in DexCom by 17.6% in the first quarter. BlackRock Group LTD now owns 69,904 shares of the medical device company’s stock worth $4,747,000 after buying an additional 10,465 shares during the last quarter. BlackRock Inc. increased its stake in DexCom by 314.5% in the first quarter. BlackRock Inc. now owns 9,321 shares of the medical device company’s stock worth $633,000 after buying an additional 7,072 shares during the last quarter. Franklin Resources Inc. increased its stake in DexCom by 7.7% in the first quarter. Franklin Resources Inc. now owns 1,476,904 shares of the medical device company’s stock worth $100,296,000 after buying an additional 106,215 shares during the last quarter. Finally, Prudential Financial Inc. increased its stake in DexCom by 37.9% in the first quarter. Prudential Financial Inc. now owns 138,269 shares of the medical device company’s stock worth $9,390,000 after buying an additional 38,032 shares during the last quarter. Institutional investors and hedge funds own 99.50% of the company’s stock.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

5 Day Chart for NASDAQ:DXCM

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.